Literature DB >> 21722815

Assessment of serum IL-1, IL-2 and IFN-γ levels in untreated pulmonary tuberculosis patients: role in pathogenesis.

Muralidhar K Katti1.   

Abstract

BACKGROUND AND AIMS: Tuberculosis (Tb) infection is controlled by cell-mediated immunity through mediation of IL-1, IL-2 and IFN-γ. In this study IL-1, IL-2 and IFN-γ were determined in serum samples of untreated pulmonary Tb and control group including apparently healthy individuals or contacts and normal healthy blood donors with an objective of understanding defect(s), if any, in synthesis of any of these cytokines that may lead to a diseased state of Tb.
METHODS: IL-1, IL-2 and IFN-γ were measured in serum samples of untreated Tb patients (n=33), contacts (n=19) and healthy individuals (n=20) by commercially available monoclonal antibody-based ELISA.
RESULTS: Statistically significant differences in IL-1 and IFN-γ concentrations between groups of pulmonary Tb and controls were observed, whereas no significant difference in IL-2 was seen.
CONCLUSIONS: In the present study, increased levels of cytokines in patients with pulmonary Tb are indicative of Th1 response. An increased level of cytokine (IFN-γ) in patients with untreated pulmonary Tb appears to be functionally defective.
Copyright © 2011 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722815     DOI: 10.1016/j.arcmed.2011.04.012

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  14 in total

1.  Modulation of iron status biomarkers in tuberculosis-diabetes co-morbidity.

Authors:  Nathella Pavan Kumar; Vaithilingam V Banurekha; Dina Nair; Chandrakumar Dolla; Paul Kumaran; Subash Babu
Journal:  Tuberculosis (Edinb)       Date:  2017-11-24       Impact factor: 3.131

2.  Common patterns and disease-related signatures in tuberculosis and sarcoidosis.

Authors:  Jeroen Maertzdorf; January Weiner; Hans-Joachim Mollenkopf; Torsten Bauer; Antje Prasse; Joachim Müller-Quernheim; Stefan H E Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

Review 3.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

4.  Effects of the Sijunzi decoction on the immunological function in rats with dextran sulfate-induced ulcerative colitis.

Authors:  Wangui Yu; Bing Lu; Hengwen Zhang; Yanxiang Zhang; Jin Yan
Journal:  Biomed Rep       Date:  2016-05-16

5.  Increased cytokines response in patients with tuberculosis complicated with chronic obstructive pulmonary disease.

Authors:  Shenjie Tang; Haiyan Cui; Lan Yao; Xiaohui Hao; Yun Shen; Lin Fan; Hua Sun; Zhanjun Zhang; Jian An Huang
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 6.  IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections.

Authors:  Jeroen Slaats; Jaap Ten Oever; Frank L van de Veerdonk; Mihai G Netea
Journal:  PLoS Pathog       Date:  2016-12-15       Impact factor: 6.823

7.  IFN-γ fails to overcome inhibition of selected macrophage activation events in response to pathogenic mycobacteria.

Authors:  Shyamala Thirunavukkarasu; Karren M Plain; Auriol C Purdie; Richard J Whittington; Kumudika de Silva
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

8.  Diminished plasma levels of common γ-chain cytokines in pulmonary tuberculosis and reversal following treatment.

Authors:  Nathella Pavan Kumar; Vaithilingam V Banurekha; Dina Nair; Subash Babu
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

Review 9.  Natural Killer Cells in Antifungal Immunity.

Authors:  Stanislaw Schmidt; Lars Tramsen; Thomas Lehrnbecher
Journal:  Front Immunol       Date:  2017-11-22       Impact factor: 7.561

10.  Inflammation responses in patients with pulmonary tuberculosis in an intensive care unit.

Authors:  Qiu-Yue Liu; Fen Han; Li-Ping Pan; Hong-Yan Jia; Qi Li; Zong-De Zhang
Journal:  Exp Ther Med       Date:  2018-01-19       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.